Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

12-month data show Genocea's genital herpes candidate stimulates immune response; shares ahead 14% premarket

Published 10/28/2016, 09:09 AM
12-month data show Genocea's genital herpes candidate stimulates immune response; shares ahead 14% premarket
  • Thinly traded micro cap Genocea Biosciences is up 14% premarket on increased volume in response to its announcement of positive long-term data for lead product candidate GEN-003, an investigational immunotherapy for the treatment of genital herpes. The results were presented at the Infectious Disease Society of America annual meeting in New Orleans, LA.
  • 12-month data from a Phase 2a clinical trial showed that GEN-003 immunization produced a multi-faceted T cell immune response to genital herpes as determined by the development of CD4+ polyfunctional T cells. The results support the previously reported data from the study which showed that a 60 ug per protein/50 ug of adjuvant dose reduced viral shedding 66% versus baseline (p<0.0001) and a 65% reduction in genital lesion rate compared to baseline (p=0.003). 30% of patients remained lesion-free 12 months after dosing.
  • Chief Scientific Officer Jessica Baker Flechtner, Ph.D., says, "We are particularly excited about the data showing the development of polyfunctional T cells which are considered to deliver a more effective immune response that those T cells which secrete only one mediator."
  • The company intends to advance GEN-003 to Phase 3 development at the dose specified above.
  • Read now After Positive P2B Results, Tiny, De-Risked Genocea Is Severely Undervalued

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.